Media About Us


  • 11 September 2018

    Researchers provide compelling evidence for multiple STI-detecting device

    Researchers provide compelling evidence for multiple STI-detecting device

    St. George's University of London / Medical Xpress

    Using mathematical modelling, researchers within the Applied Diagnostics Research and Evaluation Unit at the university concluded that a bespoke point-of care diagnostic device could significantly reduce the number of return clinical visits and the average time-to-cure from about a week to one day. The device is in early phases of development by Atlas Genetics Limited, following a grant from from Innovate UK via the Small Business Research Initiative.

  • 17 August 2018

    Blood Test Can Identify Patient Response to Prostate Cancer Treatments

    Jennifer Barrett / Specialty Pharmacy Times

  • 03 August 2018

    CeltaxsysТ cystic fibrosis drug reduces lung exacerbations in phase 2 study

    CeltaxsysТ cystic fibrosis drug reduces lung exacerbations in phase 2 study

    Conor Hale / FierceBiotech

    Celtaxsys’ oral anti-inflammatory drug for cystic fibrosis, acebilustat, cleared a phase 2 study by demonstrating meaningful improvements in pulmonary exacerbations, or the acute worsening of symptoms such as heavy coughing or shortness of breath, combined with sharp decreases in lung function following irreversible organ damage.

  • 26 July 2018

    Blood test can predict optimal treatment for advanced prostate cancer, study finds

    Blood test can predict optimal treatment for advanced prostate cancer, study finds

    EurekAlert!

    An international collaborative study between Lawson Health Research Institute, Memorial Sloan Kettering Cancer Center, the Royal Marsden and Epic Sciences is one of the first to demonstrate that a blood test can predict how patients with advanced prostate cancer will respond to specific treatments, leading to improved An international collaborative study between Lawson Health Research Institute, Memorial Sloan Kettering Cancer Center, the Royal Marsden and Epic Sciences is one of the first to demonstrate that a blood test can predict how patients with advanced prostate cancer will respond to specific treatments, leading to improved survival.survival.

  • 02 February 2018

    Syndax entered a clinicial trial collaboration with AstraZeneca

    Syndax entered a clinicial trial collaboration with AstraZeneca

    GMP News

    Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced a new clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca’s durvalumab.

  • 02 February 2018

    AstraZeneca, Syndax ally to test PD-L1 drug and CSF1R inhibitor in solid tumor patients

    AstraZeneca, Syndax ally to test PD-L1 drug and CSF1R inhibitor in solid tumor patients

    Nick Paul Taylor / FierceBiotech

    AstraZeneca and Syndax have teamed up to test immune checkpoint inhibitor Imfinzi in combination with CSF1R inhibitor SNDX-6352. Syndax is set to put the cocktail through a phase 1b solid tumor trial to equip both companies to sponsor midphase trials to demonstrate its safety and efficacy.

  • 23 January 2018

    Blockchain as a technology goes far beyond cryptocurrency application. Interview with Maxim Gorbachev, Managing Partner at RMI Partners

    Blockchain as a technology goes far beyond cryptocurrency application. Interview with Maxim Gorbachev, Managing Partner at RMI Partners

    #WBSMoscow

    As the blockchain revolution gains momentum around the world, Trescon had the opportunity to interview Maxim Gorbachev, a Managing Partner at RMI Partners, on the evolving nature of blockchain. RMI Partners is a venture capital company established in 2012, with a strategic focus on investments supporting the development of innovative biopharmaceutical products and medical technologies.

  • 19 January 2018

    Start Up Spotlight: OCON Medical Bets On A New 3D Copper Contraceptive Device

    Start Up Spotlight: OCON Medical Bets On A New 3D Copper Contraceptive Device

    Catherine Longworth / MedTech Insight

    Israeli start up OCON Medical is blazing a trail in the field of women's health with a new hormone-free contraceptive device. The company's IUB – intrauterine ball consists of copper pearls that prevent pregnancy locally within the uterus for five years.

  • 12 January 2018

    Corneal inlays need a boost from eye care providers

    Corneal inlays need a boost from eye care providers

    Healio

    The Raindrop corneal inlay from ReVision Optics and the AcuFocus Kamra corneal inlay have been implanted in thousands of eyes. Ninety-five percent of patients with these devices report being quite satisfied, according to surveys, and virtually all implanting surgeons report they would recommend the procedures to their colleagues.

  • 11 January 2018

    Genentech, Syndax expand HDAC-PD-L1 combination pact

    Genentech, Syndax expand HDAC-PD-L1 combination pact

    Nick Paul Taylor / FierceBiotech

    Genentech and Syndax have expanded their exploration of the effects of combining HDAC and PD-L1 inhibitors. The new agreement clears the Roche subsidiary to test its Tecentriq in combination with Syndax’s entinostat in a subset of breast cancer patients.